Lyell Immunopharma Q3 2026 Results: Net Loss of $45.5M, Loss Widens
Lyell Immunopharma reported total assets of $273.9 million as of September 30, 2026, a decrease from $340.1 million at the end of 2025. The company's liquidity is primarily held in cash, cash equivalents, and marketable securities totaling approximately $194 million, which it intends to use to fund the development of its lead product candidates, ronde-cel and LYL273.
- Key figure
- Net loss $45.5M